Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡